Cargando…

Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features

In contrast to primary colorectal cancer (CRC) little is known about the genomic landscape of metastasized CRC. Here we present whole genome sequencing data of metastases of 429 CRC patients participating in the pan-cancer CPCT-02 study (NCT01855477). Unsupervised clustering using mutational signatu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendelaar, Pauline A. J., Smid, Marcel, van Riet, Job, Angus, Lindsay, Labots, Mariette, Steeghs, Neeltje, Hendriks, Mathijs P., Cirkel, Geert A., van Rooijen, Johan M., Ten Tije, Albert J., Lolkema, Martijn P., Cuppen, Edwin, Sleijfer, Stefan, Martens, John W. M., Wilting, Saskia M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835235/ https://www.ncbi.nlm.nih.gov/pubmed/33495476 http://dx.doi.org/10.1038/s41467-020-20887-6

Ejemplares similares

Author Correction: Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features
por: Mendelaar, Pauline A. J., et al.
Publicado: (2021)

Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling
por: Angus, Lindsay, et al.
Publicado: (2023)

Evaluation of the Khorana, PROTECHT, and 5‐SNP scores for prediction of venous thromboembolism in patients with cancer
por: Guman, Noori A. M., et al.
Publicado: (2021)

Pan-cancer whole-genome analyses of metastatic solid tumours
por: Priestley, Peter, et al.
Publicado: (2019)

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
por: Verschoor, Noortje, et al.
Publicado: (2023)

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
por: van Dessel, Lisanne F., et al.
Publicado: (2019)

A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer
por: Isebia, Khrystany T., et al.
Publicado: (2023)

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study
por: Weeber, Fleur, et al.
Publicado: (2017)

The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets
por: van Riet, Job, et al.
Publicado: (2021)

Lost by Transcription: Fork Failures, Elevated Expression, and Clinical Consequences Related to Deletions in Metastatic Colorectal Cancer
por: Smid, Marcel, et al.
Publicado: (2022)

The mutational footprints of cancer therapies
por: Pich, Oriol, et al.
Publicado: (2019)

High‐throughput isolation of circulating tumor DNA: a comparison of automated platforms
por: van Dessel, Lisanne F., et al.
Publicado: (2018)

A pipeline for copy number profiling of single circulating tumour cells to assess intrapatient tumour heterogeneity
por: Deger, Teoman, et al.
Publicado: (2022)

A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns
por: Jiao, Wei, et al.
Publicado: (2020)

Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns
por: Jiao, Wei, et al.
Publicado: (2022)

Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer
por: Bijlsma, Rhode, et al.
Publicado: (2020)

ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients
por: Bos, Manouk K., et al.
Publicado: (2022)

The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies
por: de Joode, K., et al.
Publicado: (2023)

Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer
por: Mendelaar, Pauline A. J., et al.
Publicado: (2022)

mFast‐SeqS‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer
por: Isebia, Khrystany T., et al.
Publicado: (2023)

A tale on rabbit ears and pan-handles, the rings that rule all
por: Smid, Marcel, et al.
Publicado: (2019)

High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments
por: Deger, Teoman, et al.
Publicado: (2021)

A Systematic Review of the Use of Circulating Cell-Free DNA Dynamics to Monitor Response to Treatment in Metastatic Breast Cancer Patients
por: Jongbloed, Elisabeth M., et al.
Publicado: (2021)

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
por: Rovithi, Maria, et al.
Publicado: (2019)

Safety and Feasibility of Additional Tumor Debulking to First‐Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer
por: Gootjes, Elske C., et al.
Publicado: (2020)

Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material
por: de Leng, Wendy W. J., et al.
Publicado: (2016)

Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples
por: Mankor, Joanne M., et al.
Publicado: (2020)

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival
por: Verschoor, Noortje, et al.
Publicado: (2023)

Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients
por: Verboom, Michiel C., et al.
Publicado: (2019)

Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study
por: Verboom, Michiel C., et al.
Publicado: (2017)

Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patients
por: Mendelaar, Pauline A. J., et al.
Publicado: (2020)

Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning
por: de Jong, Anouk C., et al.
Publicado: (2023)

Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like–Induced Protein Changes in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Throughout Disease Progression
por: Bos, Manouk K., et al.
Publicado: (2022)

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
por: de Kruijff, Ingeborg E., et al.
Publicado: (2019)

Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons
por: Smid, Marcel, et al.
Publicado: (2018)

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
por: Lankheet, N A G, et al.
Publicado: (2014)

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours
por: Geurts, Birgit S., et al.
Publicado: (2023)

Circulating tumour cells are associated with histopathological growth patterns of colorectal cancer liver metastases
por: Meyer, Y. M., et al.
Publicado: (2022)

Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers
por: Weerts, Marjolein J. A., et al.
Publicado: (2018)

11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration
por: Snaterse, Gido, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9vlta729gtcve57qp99moq776a